Simple new platform for creating antibiotics developed

Image
Press Trust of India Boston
Last Updated : May 21 2016 | 3:57 PM IST
Scientists have created a new, simplified platform for antibiotic discovery that can lead to the development of new medicines and also help fight bacteria which are resistant to existing drugs.
Researchers developed a platform where they assemble eight (chemical) building blocks by a simple process to make macrolide antibiotics - which inhibit the growth of bacteria - without using erythromycin, the drug upon which all others in the class have been based since the early 1950s.
Erythromycin, which was discovered in a soil sample from the Philippines in 1949, has been on the market as a drug by 1953.
"For 60 years chemists have been very, very creative, finding clever ways to 'decorate' this molecule, making changes around its periphery to produce antibiotics that are safer, more effective, and overcome the resistance bacteria have developed," said Andrew G Myers, professor at the Harvard University.
"That process is semisynthesis, modifying the naturally occurring substance," Myers said.
In contrast, the process described in the new study involves using "eight industrial chemicals, or substances derived from them," Myers said, and manipulating them in various combinations and then testing the products against panels of disease causing bacteria.
This allows us to make new new compounds in fewer steps than was previously possible, the researchers said.
"One of the things that's quite encouraging about the data in our paper is that some of the structures we've made are active against clinical bacterial strains that are resistant to every known macrolide," Myers said.
In fact, two of the 350 compounds reported on in the study have, in initial testing, shown efficacy against a bacterium that has become resistant to vancomycin, which is known as the antibiotic of last resort, he said.
Some of the 350 compounds reported on in the study will undergo more extensive testing to evaluate their potential as candidate drugs.
The study was published in the journal Nature.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 21 2016 | 3:57 PM IST

Next Story